Genzyme Institutes Further Rationing Of Cerezyme, Fabrazyme To Build Inventory

Despite last year's manufacturing problems and the resulting shortages, biotech says 85 percent of U.S. Cerezyme patients have returned.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet